Filtered By:
Drug: Enbrel

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 39 results found since Jan 2013.

Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled. “I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.” Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery patients. “A hundred to 150 der...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news

Chronic Elevation of Tumor Necrosis Factor-{alpha} Mediates the Impairment of Leptomeningeal Arteriogenesis in db/db Mice Basic Sciences
Conclusions— These results indicate that leptomeningeal arteriogenesis is impaired in db/db mice and that suppression of the tumor necrosis factor-α response to hypoperfusion is the major contributing factor.
Source: Stroke - May 22, 2015 Category: Neurology Authors: Yukami, T., Yagita, Y., Sugiyama, Y., Oyama, N., Watanabe, A., Sasaki, T., Sakaguchi, M., Mochizuki, H., Kitagawa, K. Tags: Cerebrovascular disease/stroke, Type 2 diabetes, Other Vascular biology Basic Sciences Source Type: research

Therapeutically Targeting Tumor Necrosis Factor-{alpha}/Sphingosine-1-Phosphate Signaling Corrects Myogenic Reactivity in Subarachnoid Hemorrhage Basic Sciences
Conclusions— Vascular smooth muscle cell TNFα and sphingosine-1-phosphate signaling significantly enhance cerebral artery tone in SAH; anti-TNFα and anti–sphingosine-1-phosphate treatment may significantly improve clinical outcome.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Yagi, K., Lidington, D., Wan, H., Fares, J. C., Meissner, A., Sumiyoshi, M., Ai, J., Foltz, W. D., Nedospasov, S. A., Offermanns, S., Nagahiro, S., Macdonald, R. L., Bolz, S.-S. Tags: Animal models of human disease, Acute Cerebral Hemorrhage, Brain Circulation and Metabolism, Other Stroke Treatment - Medical, Other Vascular biology Basic Sciences Source Type: research

Effect of Inflammation on the Process of Stroke Rehabilitation and Poststroke Depression
Conclusions Stroke comprises ischemic stroke and ICH. The immuno-inflammatory process is involved in neural plasticity following events such as a hemorrhage or ischemic stroke. After ischemia, astrocytes, microglia, and MDMs play important roles during rehabilitation with the modulation of cytokines or chemokines, such as TNF-α and IL-1. Moreover, MiRNAs are also important posttranscriptional regulators in these glial mitochondrial responses to cerebral ischemia. ICH involves processes similar and different to those seen in ischemia, including neuronal injury, astrocytic and microglial/macrophage activation, and n...
Source: Frontiers in Psychiatry - April 10, 2019 Category: Psychiatry Source Type: research

Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation.
Conclusions: Perispinal etanercept can provide significant and ongoing benefits for the chronic post-stroke management of pain and greater shoulder flexion by the paretic arm. Effects are rapid and highly significant, supporting direct action on brain function.Trial registration: ACTRN12615001377527 and Universal Trial Number U1111-1174-3242. PMID: 31899977 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - January 6, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Randomized controlled trial validating the use of perispinal etanercept to reduce post-stroke disability has wide-ranging implications.
Authors: Clark IA Abstract SummaryDeveloping effective drug treatments for neurodegenerative disorders has always been hamstrung by the accepted inability of large molecules (roughly those with a molecular weight greater than 600 Daltons) to cross the blood-brain barrier (BBB) in therapeutic quantities when administered systemically. The dogma has been that a simple, non-invasive way to accomplish this goal is not possible with many agents, including biologicals, because they are too large. Various novel technologies to breach the BBB have been attempted, but with little success. A randomised double-blind, placebo-con...
Source: Expert Review of Neurotherapeutics - February 8, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Stroke Treatments with Perispinally Administered Etanercept...
South Florida Sun Sentinel recently published reports of amazing stroke recoveries.* Neurological Wellness Center Physician Augusto Ramirez M.D. confirms similar outcomes.(PRWeb July 17, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10903745.htm
Source: PRWeb: Medical Pharmaceuticals - July 18, 2013 Category: Pharmaceuticals Source Type: news

Role of Tumor Necrosis Factor-{alpha} and Natural Killer Cells in Uterine Artery Function and Pregnancy Outcome in the Stroke-Prone Spontaneously Hypertensive RatNovelty and Significance Pregnancy and Hypertension
Women with chronic hypertension are at increased risk of maternal and fetal morbidity and mortality. We have previously characterized the stroke-prone spontaneously hypertensive rat (SHRSP) as a model of deficient uterine artery function and adverse pregnancy outcome compared with the control Wistar–Kyoto. The activation of the immune system plays a role in hypertension and adverse pregnancy outcome. Therefore, we investigated the role of tumor necrosis factor-α in the SHRSP phenotype in an intervention study using etanercept (0.8 mg/kg SC) at gestational days 0, 6, 12, and 18 in pregnant SHRSP compared with vehicle-tre...
Source: Hypertension - October 11, 2016 Category: Cardiology Authors: Small, H. Y., Nosalski, R., Morgan, H., Beattie, E., Guzik, T. J., Graham, D., Delles, C. Tags: Animal Models of Human Disease, Basic Science Research, Inflammation, Hypertension, Preeclampsia Original Articles Source Type: research

Chronic cerebral aspects of long COVID, post ‐stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic
This article is about how the neurological aspects of long COVID (fatigue, neurogenic pain, loss of ability to taste or smell), can be best understood, and treated. For this purpose, the literature on TNF and brain function, both physiological and disease-associated, and how this is being applied to various long-term neurodegenerative conditions, is discussed. AbstractThe chronic neurological aspects of traumatic brain injury, post-stroke syndromes, long COVID-19, persistent Lyme disease, and influenza encephalopathy having close pathophysiological parallels that warrant being investigated in an integrated manner. A mechan...
Source: Pharmacology Research and Perspectives - February 17, 2022 Category: Drugs & Pharmacology Authors: Ian Albert Clark Tags: REVIEW ARTICLE Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia
Conclusions: Our data suggest that XPro1595 and etanercept improve functional outcome after focal cerebral ischemia by altering the peripheral immune response, changing blood and spleen cell populations and decreasing granulocyte infiltration into the brain. Blocking solTNF, using XPro1595, was just as efficient as blocking both solTNF and tmTNF using etanercept. Our findings may have implications for future treatments with anti-TNF drugs in TNF-dependent diseases.
Source: Journal of Neuroinflammation - December 12, 2014 Category: Neurology Authors: Bettina ClausenMatilda DegnNellie MartinYvonne CouchLeena KarimiMaria OrmhøjMaria-Louise MortensenHanne GredalChris GardinerIan SargentDavid SzymkowskiGéraldine PetitTomas DeierborgBente FinsenDaniel AnthonyKate Lambertsen Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Clinical presentation of children with Deficiency of Adenosine deaminase 2: A case series
Eur J Med Genet. 2022 Jun 28;65(8):104555. doi: 10.1016/j.ejmg.2022.104555. Online ahead of print.ABSTRACTDeficiency of Adenosine deaminase 2 (DADA2) is a monogenic inflammatory disease, caused by mutations in ADA2 gene, which encodes an extracellular enzyme acting as a monocyte differentiation factor. DADA2 is first described with the clinical picture resembling polyarteritis nodosa, including livedo racemose, recurrent fever, musculoskeletal complaints. Besides, some patients have cytopenia, lymphoproliferation and mild to moderate immunodeficiency. The most crucial complication of DADA2 is neurological involvement, espe...
Source: European Journal of Medical Genetics - July 1, 2022 Category: Genetics & Stem Cells Authors: Rabia Miray Kisla Ekinci Ozlem Anlas Ozge Ozalp Source Type: research